Open AccessDouble-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection
Author(s) -
G Sheehan,
G. K. M. Harding,
D. Haase,
Marian Thomson,
B. Urias,
J. S. Kennedy,
Daryl J. Hoban,
Allan R. Ronald
Publication year - 1988
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.32.8.1292
Subject(s) - norfloxacin , placebo , bacteriuria , medicine , urinary system , double blind , randomized controlled trial , adverse effect , antibacterial agent , urine , urology , surgery , antibiotics , ciprofloxacin , biology , microbiology and biotechnology , alternative medicine , pathology
We evaluated the benefits of prolonging norfloxacin therapy from 12 to 24 weeks for complicated urinary tract infection in a double-blind, randomized, placebo-controlled study. During the second 12 weeks, norfloxacin was superior to placebo (P less than 0.05) in suppressing bacteriuria. Adverse effects were common but mostly confined to the initial 12 weeks.